Economic Studies on Non-Communicable Diseases and Injuries in India: A Systematic Review

Applied Health Economics and Health Policy

Volumn 16, Issue 3, 2018, Pages 303-315

  Gupta, Indrani ^a   Roy, Arjun ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; ECONOMIC ASPECT; ECONOMIC EVALUATION; ENDOCRINE DISEASE; FUNDING; GASTROINTESTINAL DISEASE; GEOGRAPHIC DISTRIBUTION; HEALTH INSURANCE; HUMAN; INDIA; INJURY; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; NON COMMUNICABLE DISEASE; REVIEW; RURAL AREA; SOCIOECONOMICS; SYSTEMATIC REVIEW; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; HEALTH CARE COST; PUBLIC HEALTH;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; HEALTH EXPENDITURES; INDIA; NONCOMMUNICABLE DISEASES; PUBLIC HEALTH; WOUNDS AND INJURIES;

EID: 85044757525     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-018-0370-1     Document Type: Review

References (118)

1. World Health Organization. Noncommunicable diseases country profiles 2014. http://apps.who.int/iris/bitstream/10665/128038/1/9789241507509_eng.pdf. Accessed 2 May 2017.
2. World Health Organization. India NCD Country Profile 2014. http://www.who.int/nmh/countries/ind_en.pdf. Accessed 2 May 2017.
3. Reddy KS, et al. Responding to the threat of chronic diseases in India. Lancet. 2005;366(9498):1744–9.
4. Selvaraj S, Abrol D, Gopakumar K. Access to medicines in India. New Delhi: Academic Foundation; 2014.
5. World Health Organization. General government expenditure on health (GGHE) as % of THE. Global Health Expenditure Database 2012. http://apps.who.int/nha/ database/Select/Indicators/en. Accessed 2 May 2017.
6. Government of India. Ministry of Health and Family Welfare. National Health Accounts Estimates for India, 2014–15. https://mohfw.gov.in/sites/default/files/National%20Health%20Accounts%20Estimates%20Report%202014-15.pdf. Accessed 7 Mar 2018.
7. Jamison DT, Breman JG, Measham AR, et al., editors. Disease control priorities in developing countries. 2nd ed. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2006 (Co-published by Oxford University Press, New York). Available from: https://www.ncbi.nlm.nih.gov/books/NBK11728/.
8. Raftery J, Powell J. Health technology assessment in the UK. Lancet. 2013;382:1278–85.
9. Downey LE, Mehndiratta A, Grover A, Gauba V, Sheikh K, Prinja S, Singh R, Cluzeau FA, Dabak S, Teerawattananon Y, Kumar S, Swaminathan S. Institutionalising health technology assessment: establishing the Medical Technology Assessment Board in India. BMJ Glob Health. 2017;2(2):e000259. 10.1136/bmjgh-2016-000259.
10. Centers for Disease Control and Prevention. Public health economics and tools. 2017. https://www.cdc.gov/stltpublichealth/pheconomics/. Accessed 4 Nov 2017.
11. Vos T, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2013; 2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2015;388(10053):1545–602.
12. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.
13. Aggarwal K, et al. Comparison of clinical and cost-effectiveness of psoralen + ultraviolet A versus psoralen + sunlight in the treatment of chronic plaque psoriasis in a developing economy. Int J Dermatol. 2013;52(4):478–85.
14. Ahmad A, et al. A comparison of enoxaparin with unfractionated heparins in patients with coronary heart disease in an emergency department in rural South Indian tertiary care teaching hospital. Indian J Pharmacol. 2015;47(1):90–4.
15. Ahuja RB, Goswami P. Cost of providing inpatient burn care in a tertiary, teaching, hospital of North India. Burns. 2013;39(4):558–64.
16. Alam K, Mahal A. The economic burden of angina on households in South Asia. BMC Public Health. 2014;14:179.
17. Anchala R, et al. Evaluation of effectiveness and cost-effectiveness of a clinical decision support system in managing hypertension in resource constrained primary health care settings: results from a cluster randomized trial. J Am Heart Assoc. 2015;4(1):e001213.
18. Basu S, et al. Palm oil taxes and cardiovascular disease mortality in India: economic-epidemiologic model. BMJ. 2013;347:f6048.
19. Basu S, Bendavid E, Sood N. Health and economic implications of national treatment coverage for cardiovascular disease in india: cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2015;8(6):541–51.
20. Basu S, et al. Averting obesity and type 2 diabetes in India through sugar-sweetened beverage taxation: an economic-epidemiologic modeling study. PLoS Med. 2014;11(1):e1001582.
21. Basu S, Yudkin JS, Sussman JB, Millett C, Hayward RA. Alternative strategies to achieve cardiovascular mortality goals in China and India: a microsimulation of target- versus risk-based blood pressure treatment. Circulation. 2016;133(9):840–8.
22. Burke MJ, Shenton RC, Taylor MJ. The economics of screening infants at risk of hearing impairment: an international analysis. Int J Pediatr Otorhinolaryngol. 2012;76(2):212–8.
23. Buttorff C, et al. Economic evaluation of a task-shifting intervention for common mental disorders in India. Bull World Health Org. 2012;90(11):813–21.
24. Campbell A, et al. Scalable, sustainable cost-effective surgical care: a model for safety and quality in the developing world, part II: program development and quality care. J Craniofac Surg. 2014;25(5):1680–4.
25. Cecchini M, et al. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet. 2010;376(9754):1775–84.
26. Chemmanam T, et al. A prospective study on the cost-effective utilization of long-term inpatient video-EEG monitoring in a developing country. J Clin Neurophysiol. 2009;26(2):123–8.
27. Chisholm D, et al. Estimating the cost of implementing district mental healthcare plans in five low- and middle-income countries: the PRIME study. Br J Psychiatry. 2016;208(Suppl 56):s71–8.
28. Daivadanam M, et al. Catastrophic health expenditure and coping strategies associated with acute coronary syndrome in Kerala, India. Indian J Med Res. 2012;136(4):585–92.
29. Das K, et al. Evaluation of socio-economic factors causing discontinuation of epilepsy treatment resulting in seizure recurrence: a study in an urban epilepsy clinic in India. Seizure. 2007;16(7):601–7.
30. Das K, et al. Discontinuation of secondary preventive treatment of stroke: an unexplored scenario in India. Clin Neurol Neurosurg. 2010;112(9):766–9.
31. Dharmarajan S, et al. Out-of-pocket and catastrophic expenditure on treatment of haemophilia by Indian families. Haemophilia. 2014;20(3):382–7.
32. Diaz M, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer. 2008;99(2):230–8.
33. Donaldson EA, et al. A cost-effectiveness analysis of India’s 2008 prohibition of smoking in public places in Gujarat. Int J Environ Res Public Health. 2011;8(5):1271–86.
34. Dorairajan N, et al. Day care surgery in a metropolitan government hospital setting—Indian scenario. Int Surg. 2010;95(1):21–6.
35. Dranitsaris G, Truter I, Lubbe MS. The development of a value based pricing index for new drugs in metastatic colorectal cancer. Eur J Cancer. 2011;47(9):1299–304.
36. Dranitsaris G, et al. Improving patient access to cancer drugs in India: using economic modeling to estimate a more affordable drug cost based on measures of societal value. Int J Technol Assess Health Care. 2011;27(1):23–30.
37. Engelgau MM, Karan A, Mahal A. The economic impact of non-communicable diseases on households in India. Glob Health. 2012;8:9.
38. Ghatak N, Trehan A, Bansal D. Financial burden of therapy in families with a child with acute lymphoblastic leukemia: report from north India. Support Care Cancer. 2016;24(1):103–8.
39. Goldhaber-Fiebert JD, et al. Inpatient treatment of diabetic patients in Asia: evidence from India, China, Thailand and Malaysia. Diabet Med. 2010;27(1):101–8.
40. Goyal S, et al. Risk factors and costs of oral cancer in a tertiary care hospital in Delhi. Asian Pac J Cancer Prev. 2014;15(4):1659–65.
41. Gupta S, et al. Challenges of implementing universal newborn hearing screening at a tertiary care centre from India. Indian J Pediatr. 2015;82(8):688–93.
42. Gupta V, et al. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes. J Med Econ. 2015;18(4):263–72.
43. Hackenberg B, et al. Measuring and comparing the cost-effectiveness of surgical care delivery in low-resource settings: cleft lip and palate as a model. J Craniofac Surg. 2015;26(4):1121–5.
44. Haripriya A, et al. Efficacy of intracameral moxifloxacin endophthalmitis prophylaxis at Aravind Eye Hospital. Ophthalmology. 2016;123(2):302–8.
45. Home P, et al. An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes. J Med Econ. 2015;18(3):230–40.
46. Huffman MD, et al. A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low- and middle-income countries. PLoS One. 2011;6(6):e20821.
47. Jansen LA, et al. Improving patient follow-up in developing regions. J Craniofac Surg. 2014;25(5):1640–4.
48. John RM, Sung HY, Max W. Economic cost of tobacco use in India, 2004. Tob Control. 2009;18(2):138–43.
49. Joshi A, et al. Burden of healthcare utilization and out-of-pocket costs among individuals with NCDs in an Indian setting. J Community Health. 2013;38(2):320–7.
50. Karan A, Engelgau M, Mahal A. The household-level economic burden of heart disease in India. Trop Med Int Health. 2014;19(5):581–91.
51. Kesavadev J, et al. Cost-effective use of telemedicine and self-monitoring of blood glucose via Diabetes Tele Management System (DTMS) to achieve target glycosylated hemoglobin values without serious symptomatic hypoglycemia in 1,000 subjects with type 2 diabetes mellitus—a retrospective study. Diabetes Technol Ther. 2012;14(9):772–6.
52. Khatib R, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet. 2016;387(10013):61–9.
53. Kotwani A. Availability, price and affordability of asthma medicines in five Indian states. Int J Tuberc Lung Dis. 2009;13(5):574–9.
54. Kumar A, Gupta NP, Hemal AK. A single institution experience of 141 cases of laparoscopic radical nephrectomy with cost-reductive measures. J Endourol. 2009;23(3):445–9.
55. Kumar A, Nagpal J, Bhartia A. Direct cost of ambulatory care of type 2 diabetes in the middle and high income group populace of Delhi: the DEDICOM survey. J Assoc Physicians India. 2008;56:667–74.
56. Kumar GA, et al. Burden of out-of-pocket expenditure for road traffic injuries in urban India. BMC Health Serv Res. 2012;12:285.
57. Kumpatla S, et al. The costs of treating long term diabetic complications in a developing country: a study from India. JAPI. 2013;61:17.
58. Lahiri S, Tempesti T, Gangopadhyay S. Is There an Economic Case for Training Intervention in the Manual Material Handling Sector of Developing Countries? J Occup Environ Med. 2016;58(2):207–14.
59. Lamy A, et al. The cost implications of off-pump versus on-pump coronary artery bypass graft surgery at one year. Ann Thorac Surg. 2014;98(5):1620–5.
60. Levesque JF, et al. Affording what’s free and paying for choice: comparing the cost of public and private hospitalizations in urban Kerala. Int J Health Plann Manag. 2007;22(2):159–74.
61. Linde M, Steiner TJ, Chisholm D. Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries. J Headache Pain. 2015;16:15.
62. Lohse N, Marseille E, Kahn JG. Development of a model to assess the cost-effectiveness of gestational diabetes mellitus screening and lifestyle change for the prevention of type 2 diabetes mellitus. Int J Gynecol Obstet. 2011;115:S20–5.
63. Lopes Gde L. Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India. Ann Oncol. 2013;24(Suppl 5):v13–6.
64. Mahal A, et al. The economic burden of cancers on Indian households. PLoS One. 2013;8(8):e71853.
65. Marseille E, et al. The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel. J Matern Fetal Neonatal Med. 2013;26(8):802–10.
66. Megiddo I, et al. Cost-effectiveness of treatment and secondary prevention of acute myocardial infarction in India: a modeling study. Glob Heart. 2014;9(4):391.e3–398.e3.
67. Megiddo I, et al. Health and economic benefits of public financing of epilepsy treatment in India: an agent-based simulation model. Epilepsia. 2016;57(3):464–74.
68. Misra UK, et al. Cost of status epilepticus in a tertiary care hospital in India. Seizure. 2015;31:94–8.
69. Muranjan M, Vijayalakshmi P. The unforeseen toll of birth defects and their economic burden at a tertiary care public institute in Mumbai. Indian J Pediatr. 2014;81(10):1005–9.
70. Nagengast ES, et al. Providing more than health care: the dynamics of humanitarian surgery efforts on the local microeconomy. J Craniofac Surg. 2014;25(5):1622–5.
71. Nair KS, et al. Cost of treatment for cancer: experiences of patients in public hospitals in India. Asian Pac J Cancer Prev. 2013;14(9):5049–54.
72. Natarajan S, Rudrawar P. Bronchiectasis in western India: clinical presentations and socio-economic burden. J Indian Med Assoc. 2014;112(2):89–92.
73. Okonkwo QL, et al. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Inst. 2008;100(18):1290–300.
74. Padhi NR, Padhi P. Use of external fixators for open tibial injuries in the rural third world: panacea of the poor? Injury. 2007;38(2):150–9.
75. Pakseresht S, et al. Expenditure audit of women with breast cancer in a tertiary care hospital of Delhi. Indian J Cancer. 2011;48(4):428–37.
76. Patankar A, Trivedi P. Monetary burden of health impacts of air pollution in Mumbai, India: implications for public health policy. Public Health. 2011;125(3):157–64.
77. Patel RS, et al. Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: a pharmacoeconomic comparison of antihypertensive efficacy of beta blockers. Indian J Pharmacol. 2014;46(5):485–9.
78. Patel V, et al. Prioritizing health problems in women in developing countries: comparing the financial burden of reproductive tract infections, anaemia and depressive disorders in a community survey in India. Trop Med Int Health. 2007;12(1):130–9.
79. Pati S, et al. Non communicable disease multimorbidity and associated health care utilization and expenditures in India: cross-sectional study. BMC Health Serv Res. 2014;14:451.
80. Polack S, et al. Utility values associated with diabetic retinopathy in Chennai, India. Ophthalmic Epidemiol. 2015;22(1):20–7.
81. Prajna VN, et al. Economic analysis of corneal ulcers in South India. Cornea. 2007;26(2):119–22.
82. Rachapelle S, et al. The cost–utility of telemedicine to screen for diabetic retinopathy in India. Ophthalmology. 2013;120(3):566–73.
83. Raj M, et al. Micro-economic impact of congenital heart surgery: results of a prospective study from a limited-resource setting. PLoS One. 2015;10(6):e0131348.
84. Ramachandran A. Socio-economic burden of diabetes in India. J Assoc Physicians India. 2007;55(Suppl):9–12.
85. Ramachandran A, et al. Increasing expenditure on health care incurred by diabetic subjects in a developing country: a study from India. Diabetes Care. 2007;30(2):252–6.
86. Ramachandran A, et al. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care. 2007;30(10):2548–52.
87. Ranade AA, et al. Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India. Ann Oncol. 2013;24(Suppl 5):v6–12.
88. Rao GN, Bharath S. Cost of dementia care in India: delusion or reality? Indian J Public Health. 2013;57(2):71–7.
89. Rao GN, et al. The burden attributable to headache disorders in India: estimates from a community-based study in Karnataka State. J Headache Pain. 2015;16:94.
90. Rao KD, Bhatnagar A, Murphy A. Socio-economic inequalities in the financing of cardiovascular and diabetes inpatient treatment in India. Indian J Med Res. 2011;133:57–63.
91. Reddy GM, et al. Extent and determinants of cost of road traffic injuries in an Indian city. Indian J Med Sci. 2009;63(12):549–56.
92. Reddy GM, Singh A, Singh D. Community based estimation of extent and determinants of cost of injuries in a north Indian city. Indian J Med Sci. 2012;66(1–2):23–9.
93. Reddy VK, et al. Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome. Indian J Pharmacol. 2014;46(4):372–7.
94. Rengasamy S, et al. Comparison of 2 days versus 5 days of octreotide infusion along with endoscopic therapy in preventing early rebleed from esophageal varices: a randomized clinical study. Eur J Gastroenterol Hepatol. 2015;27(4):386–92.
95. Schulman-Marcus J, Prabhakaran D, Gaziano TA. Pre-hospital ECG for acute coronary syndrome in urban India: a cost-effectiveness analysis. BMC Cardiovasc Disord. 2010;10:13.
96. Shafie AA, et al. An analysis of the short-and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes. Diabetes Res Clin Pract. 2014;106(2):319–27.
97. Singh A, et al. Risk factors for oral diseases among workers with and without dental insurance in a national social security scheme in India. Int Dent J. 2014;64(2):89–95.
98. Somaiya M, et al. Changes in cost of treating schizophrenia: comparison of two studies done a decade apart. Psychiatry Res. 2014;215(3):547–53.
99. Soudarssanane M, et al. Rheumatic fever and rheumatic heart disease: primary prevention is the cost effective option. Indian J Pediatr. 2007;74(6):567–70.
100. Srivastava A, Mohanty SK. Age and sex pattern of cardiovascular mortality, hospitalisation and associated cost in India. PLoS One. 2013;8(5):e62134.
101. Subramanian S, et al. Cost-effectiveness of oral cancer screening: results from a cluster randomized controlled trial in India. Bull World Health Org. 2009;87(3):200–6.
102. Sudhindran S, et al. Cost and efficacy of immunosuppression using generic products following living donor liver transplantation in India. Indian J Gastroenterol. 2012;31(1):20–3.
103. Suh GH, et al. International price comparisons of Alzheimer’s drugs: a way to close the affordability gap. Int Psychogeriatr. 2009;21(6):1116–26.
104. Sur D, Mukhopadhyay SP. A study on smoking habits among slum dwellers and the impact on health and economics. J Indian Med Assoc. 2007;105(9):492–8.
105. Tharkar S, et al. The socioeconomics of diabetes from a developing country: a population based cost of illness study. Diabetes Res Clin Pract. 2010;89(3):334–40.
106. Tharkar S, Satyavani K, Viswanathan V. Cost of medical care among type 2 diabetic patients with a co-morbid condition—Hypertension in India. Diabetes Res Clin Pract. 2009;83(2):263–7.
107. Trani JF, et al. Mental illness, poverty and stigma in India: a case-control study. BMJ Open. 2015;5(2):e006355.
108. Wani MA, et al. Cost analysis of in-patient cancer chemotherapy at a tertiary care hospital. J Cancer Res Ther. 2013;9(3):397–401.
109. Gavaza P, et al. The state of health economic research in South Africa. Pharmacoeconomics. 2012;30(10):925–40.
110. Teerawattananon Y, Russell S, Mugford M. A systematic review of economic evaluation literature in Thailand. Pharmacoeconomics. 2007;25(6):467–79.
111. Tran BX, et al. A systematic review of scope and quality of health economic evaluation studies in Vietnam. PLoS One. 2014;9(8):e103825.
112. UK and India to work together on evidence-informed healthcare policy and practice. 2013. https://www.gov.uk/government/world-location-news/uk-and-india-to-work-together-on-evidence-informed-healthcare-policy-and-practice. Accessed 4 Nov 2017.
113. Prinja S, et al. A systematic review of the state of economic evaluation for health care in India. Appl Health Econ Health Policy. 2015;13(6):595–613.
114. Karan A, Yip W, Mahal A. Extending health insurance to the poor in India: an impact evaluation of Rashtriya Swasthya Bima Yojana on out of pocket spending for healthcare. Soc Sci Med. 2017;181(Supplement C):83–92.
115. Bloom DE, Cafiero ET, McGovern ME, Prettner K, Stanciole A, Weiss J, Bakkila S, Rosenberg L. The economic impact of non-communicable disease in China and India: estimates, projections, and comparisons. NBER Working Paper No. 19335. http://www.nber.org/papers/w19335.
116. Garg CC, Evans D. What is the impact of non-communicable diseases on national health expenditures: a synthesis of available data. Geneva: World Health Organization; 2011.
117. Gupta I, Kandamuthan S, Upadhyaya D. Economic impact of cardiovascular diseases in India. New Delhi: Institute of Economic Growth University of Delhi; 2006.
118. Mahal AS, Karan A, Engelgau M. Economic implications of non-communicable disease for India. Washington, DC: World Bank; 2010.